Sponsor Deadline
Posted: 3/20/2024

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

The purpose of this FOA is to provide investigators working on the development of novel therapeutic products for HIV and HIV-associated co-infections (hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis) with a mechanism to request NIAID DAIDS preclinical services to fill gaps in their product development efforts and facilitate the advancement of promising therapeutics from bench to clinics.


  • Letter of Intent Due Date(s): 30 days prior to the application due date

  • AIDS Application Due Dates: Sep 1, 2022; Jan 17, 2023; Sep 1, 2023; Jan 17, 2024; Sep 1, 2024; Jan 17, 2025

PAR-22-185 Expiration Date January 18, 2025

Eligibility Requirements

A separate application is required for each service area (A-D). Applicants may submit more than one application per each service area provided they are distinct.

Funding Type